Absolute lymphocyte counts of HD and NT1 patients.

<p>Absolute lymphocyte counts of HD and NT1 patients.</p

Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells - Fig 2

<p><b>Cytokines profiles after PMA/ionomycine activation</b> in CD4⁺ (A) and CD8⁺ (B) T cells or directly in plasma (C) of HD (n = 4–5) and NT1 patients (n = 6–8).</p

Narcolepsy Type 1 Is Associated with a Systemic Increase and Activation of Regulatory T Cells and with a Systemic Activation of Global T Cells - Fig 3

<p><b>Tregs percentages and phenotype according to NT1 (A-B) and to H1N1 (C-D) status.</b> 32 HD, 31 NT1 patients (including 14 H1N1 and 17 non H1N1 NT1 patients), were assayed for Tregs phenotypes.</p

Demographic and clinical parameters of healthy donors (HD) and H1N1 or non H1N1 NT1 patients.

<p>Demographic and clinical parameters of healthy donors (HD) and H1N1 or non H1N1 NT1 patients.</p

CD4⁺ and CD8⁺ T cell differentiation and activation phenotypes according to NT1 and H1N1 status.

<p>Central memory (CM), effector memory (EM) and naïve CD4⁺ and CD8⁺ T cells in peripheral blood were characterized for HD and NT1 patients (A and C) and for H1N1 or non H1N1 NT1 patients (E and G). Activation markers for CD4⁺ and CD8⁺ T cells in peripheral blood were characterized for HD and NT1 patients (B and D) and for H1N1 or non H1N1 NT1 patients (F and H).</p

Association signal at the mapping intervals flanking rs34593439 and rs7553711.

<p>Association scores at 15q25.1 (panel A) and 1q25.1 (panel B). Genotyped (diamonds) and imputed (circles) SNPs are indicated and the top genotyped SNP in the interval is outlined in orange. A SNP in 15q25.1 previously associated with Diabetes is outlined in blue. The degree of red color in each diamond or circle indicates the strength of LD with the top SNP (on a scale shown in the legend at the upper left hand corner of the plot). The X-axis shows the chromosome and physical distance (kb) from the human genome reference sequence (hg19), the left Y-axis shows the negative base ten logarithm of the p-value and the right Y-axis shows recombination rate (cM/Mb) as a navy line. The genome-wide significance threshold (P<5×10⁻⁸) is given by the dashed grey line. Genes in the regions are annotated at the bottom as green arrows. Also indicated in 1q25.1 is a ∼130 kb region with no SNPs on the ImmunoChip.</p

Sample collections.

*<p>Numbers of samples by country of origin are listed in the <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003270#s3" target="_blank">Methods</a> section.</p><p>Case cohort names represent location of genotyping, and do not reflect country of origin of samples.</p

Manhattan Plot of association statistics.

<p>The significance threshold used (blue line) was P = 5×10⁻⁸; The insets depict plots of 1) association results in a broad region encompassing the HLA locus (chr 6:24,067–35,474 kb) that were excluded from the present analysis (see <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003270#s3" target="_blank">Methods</a>) and 2) QQ plot of results for 109,777 markers after excluding a 1 Mb window surrounding the associated loci (λ = 1.004). The inflation statistic for all 111,240 tested markers is 1.04.</p

Non-HLA narcolepsy risk variant loci reaching genome-wide significance.

<p>Chr.: Chromosome; BP: position according to NCBI build 36 (Hg18) coordinates; MAF_N: minor allele frequency in narcolepsy (_N) and controls (_C); P: P value according to variance component model (EMMAX). EMMAX does not provide OR (Odds Ratio) or adjusted allele frequencies, therefore MAF, OR, and 95% confidence intervals (CI) were calculated with Plink on subset of 8,474 samples with the greatest PCA homogeneity (see Figure S2; EV 11.21<0.004, EV 4.12<0.01).</p